AI assistant
Editas Medicine, Inc. — Director's Dealing 2018
Oct 19, 2018
33260_dirs_2018-10-19_73ddfde5-81a4-4758-bdb1-b7eb5c0836c8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2018-10-17
Reporting Person: Myer Vickesh (Chief Technology Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-10-17 | Common Stock | M | 3000 | $0.65 | Acquired | 3000 | Direct |
| 2018-10-17 | Common Stock | S | 3000 | $28.87 | Disposed | 0 | Direct |
| 2018-10-18 | Common Stock | M | 4000 | $11.21 | Acquired | 4000 | Direct |
| 2018-10-18 | Common Stock | S | 4000 | $29.44 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-10-17 | Stock Option (right to buy) | $0.65 | M | 3000 | Disposed | 2025-04-29 | Common Stock (3000) | Direct |
| 2018-10-18 | Stock Option (right to buy) | $11.21 | M | 4000 | Disposed | 2025-10-29 | Common Stock (4000) | Direct |
Footnotes
F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.
F2: This transaction was executed in multiple trades at prices ranging from $28.21 to $29.08. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and the prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $29.10 to $29.54. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and the prices at which the transaction was effected.
F4: This option was granted on April 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019.
F5: This option was granted on October 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on October 27, 2016 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 27, 2019.